Tumor immune response and immunotherapy in gastric cancer

키워드

참고문헌 (112)

1. Kaufman HL, "The promise of Immunooncology : implications for defining the value of cancer treatment", J Immunother Cancer, 7, pp.129~ (2019)
2. Chen DS, "Oncology meets immunology : the cancerimmunity cycle", Immunity, 39, pp.1~10 (2013)
3. Kim JM, "Immune escape to PD-L1", PD-1 blockade : seven steps to success(or failure), 2016, pp.27, 1492~1504
4. Melief CJ, "Therapeutic cancer vaccines", J Clin Invest, 125, pp.3401~3412 (2015)
5. Gajewski TF, "Innate and adaptive immune cells in the tumor microenvironment", Nat Immunol, 14, pp.1014~1022 (2013)
6. van der Burg SH, "Vaccines for established cancer : overcoming the challenges posed by immune evasion", Nat Rev Cancer, 16, pp.219~233 (2016)
7. Welters MJ, "Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine", Clin Cancer Res, 14, pp.178~187 (2008)
8. Coulie PG, "Tumour antigens recognized by T lymphocytes : at the core of cancer immunotherapy", Nat Rev Cancer, 14, pp.135~146 (2014)
9. Dranoff G, "Cytokines in cancer pathogenesis and cancer therapy", Nat Rev Cancer, 4, pp.11~22 (2004)
10. Houghton AN, "Immune recognition of self in immunity against cancer", J Clin Invest, 114, pp.468~471 (2004)
11. Schwartz RH, "T cell anergy", Annu Rev Immunol, 21, pp.305~334 (2003)
12. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
13. Chen DS, "Elements of cancer immunity and the cancerimmune set point", Nature, 541, pp.321~330 (2017)
14. Tanaka A, "Regulatory T cells in cancer immunotherapy", Cell Res, 27, pp.109~118 (2017)
15. Vesely MD, "Natural innate and adaptive immunity to cancer", Annu Rev Immunol, 29, pp.235~271 (2011)
16. Dunn GP, "The three Es of cancer immunoediting", Annu Rev Immunol, 22, pp.329~360 (2004)
17. Taube JM, "Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape", Sci Transl Med, 4, pp.127ra37~ (2012)
18. Buchbinder EI, "CTLA-4 and PD-1 pathways : similarities, differences, and implications of their inhibition", Am J Clin Oncol, 39, pp.98~106 (2016)
19. Schildberg FA, "Coinhibitory pathways in the B7-CD28 ligand-receptor family", Immunity, 44, pp.955~972 (2016)
20. Huard B, "CD4", major histocompatibility complex class II interaction analyzed with CD4-and lymphocyte activation gene-3(LAG-3)-Ig fusion proteins, 1995, pp.25, 2718~2721
21. Liu B, "Liver sinusoidal endothelial cell lectin inhibits CTL-dependent virus clearance in mouse models of viral hepatitis", J Immunol, 190, pp.4185~4195 (2013)
22. Anderson AC, "Lag-3, Tim-3, and TIGIT : co-inhibitory receptors with specialized functions in immune regulation", Immunity, 44, pp.989~1004 (2016)
23. Parham P, "Population biology of antigen presentation by MHC class I molecules", Science, 272, pp.67~74 (1996)
24. Garrido F, "MHC antigens and tumor escape from immune surveillance", Adv Cancer Res, 83, pp.117~158 (2001)
25. del Campo AB, "Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma", Int J Cancer, 134, pp.102~113 (2014)
26. Kumar V, "Robbins and Cotran pathologic basis of disease" (2014), Elsevier
27. Jiang W, "Tumor-infiltrating immune cells and prognosis in gastric cancer : a systematic review and meta-analysis", Oncotarget, 8, pp.62312~62329 (2017)
28. Zheng X, "Prognostic role of tumor-infiltrating lymphocytes in gastric cancer : a meta-analysis", Oncotarget, 8, pp.57386~57398 (2017)
29. Lee HE, "Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer", Br J Cancer, 99, pp.1704~1711 (2008)
30. Haas M, "Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia", BMC Gastroenterol, 9, pp.65~ (2009)
31. Shen Z, "Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+", CD8+ ratio are associated with adverse prognosis in resectable gastric cancer, 2010, pp.136, 1585~1595
32. Kim HI, "The ratio of intra-tumoral regulatory T cells(Foxp3+)", helper T cells(CD4+)is a prognostic factor and associated with recurrence pattern in gastric cardia cancer, 2011, pp.104, 728~733
33. Kim KJ, "Prognostic implications of tumorinfiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers", Hum Pathol, 45, pp.285~293 (2014)
34. Li K, "Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer", Int J Clin Exp Pathol, 8, pp.14725~14732 (2015)
35. Liu K, "Tumor-infiltrating immune cells are associated with prognosis of gastric cancer", Medicine(Baltimore), 94, pp.e1631~ (2015)
36. Hennequin A, "Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients", Oncoimmunology, 5, pp.e1054598~ (2016)
37. Kim JW, "Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer", Gastric Cancer, 19, pp.42~52 (2016)
38. Giampieri R, "Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy", Gastric Cancer, 20, pp.156~163 (2017)
39. Kawazoe A, "Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients", Gastric Cancer, 20, pp.407~415 (2017)
40. Koh J, "Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumorinfiltrating lymphocytes in stage II and III gastric cancer patients", Oncotarget, 8, pp.26356~26367 (2017)
41. Simon Pernot, "Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance", Gastric Cancer, 23(1), pp.73~81 (2020), Springer Science and Business Media LLC[DOI]
42. Kim JY, "Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact", Gastric Cancer, 22, pp.1164~1175 (2019)
43. Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
44. Charalampakis N, "Medical management of gastric cancer : a 2017 update", Cancer Med, 7, pp.123~133 (2018)
45. Kiyozumi Y, "Update on targeted therapy and immune therapy for gastric cancer, 2018", J Cancer Metastasis Treat, 4, pp.31~ (2018)
46. Kang YK, "Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens(ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.2461~2471 (2017)
47. Fashoyin-Aje L, "FDA approval summary : pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1", Oncologist, 24, pp.103~109 (2019)
48. Marcus L, "FDA approval summary : pembrolizumab for the treatment of microsatellite instability-high solid tumors", Clin Cancer Res, 25, pp.3753~3758 (2019)
49. Muro K, "Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012) : a multicentre, open-label, phase 1b trial", Lancet Oncol, 17, pp.717~726 (2016)
50. Fuchs CS, "Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer : phase 2 clinical KEYNOTE-059 Trial", JAMA Oncol, 4, pp.e180013~ (2018)
51. Shitara K, "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer(KEYNOTE-061) : a randomised, open-label, controlled, phase 3 trial", Lancet, 392, pp.123~133 (2018)
52. Tabernero J, "Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction(G", GEJ)adenocarcinoma : the phase III KEYNOTE-062 study, 2019, pp.37, LBA4007~
53. Janjigian YY, "CheckMate-032 study : efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer", J Clin Oncol, 36, pp.2836~2844 (2018)
54. Boku N, "Safety and efficacy of nivolumab in combination with S-1", capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric, Ann Oncol, pp.2019, 30[DOI]
55. Janjigian YY, "Checkmate 649: a randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo)plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer", J Clin Oncol, 35, pp.TPS213~ (2017)
56. Kelly RJ, "Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer", J Clin Oncol, 36, pp.4031~ (2018)
57. Bang YJ, "Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as thirdline treatment of patients with advanced gastric or gastro-oesophageal junction cancer : primary analysis of JAVELIN Gastric 300", Ann Oncol, 29, pp.2052~2060 (2018)
58. Moehler M, "Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer : JAVELIN Gastric 100 study design", Future Oncol, 15, pp.567~577 (2019)
59. "A phase 1b/2 study of MEDI4736 with tremelimumab, MEDI4736or tremelimumab monotherapy in gastric or GEJ adenocarcinoma" (2015)[URL]
60. "An investigational immuno-therapy study to assess the safety, tolerability and effectiveness of anti-LAG-3 with and without anti-PD-1 in the treatment of solid tumors" (2013)[URL]
61. Ishida Y, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J, 11, pp.3887~3895 (1992)
62. Ribas A, "Tumor immunotherapy directed at PD-1", N Engl J Med, 366, pp.2517~2519 (2012)
63. Qing Y, "Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer", Drug Des Devel Ther, 9, pp.901~909 (2015)
64. Wu C, "Immunohistochemical localization of programmed death-1 ligand-1(PD-L1)in gastric carcinoma and its clinical significance", Acta Histochem, 108, pp.19~24 (2006)
65. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
66. "Interpretation manual: gastric or gastroesophageal junction adenocarcinoma. PD-L1 IHC 22C3 pharmDx interpretation manual:gastric or gastroesophageal juction adenocarcinoma" (2018)[URL]
67. Batenchuk C, "A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies", J Clin Pathol, 71, pp.1078~1083 (2018)
68. Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
69. Ratti M, "Microsatellite instability in gastric cancer : molecular bases, clinical perspectives, and new treatment approaches", Cell Mol Life Sci, 75, pp.4151~4162 (2018)
70. Polom K, "Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer", Br J Surg, 105, pp.159~167 (2018)
71. 김주연, "Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes", Journal of Pathology and Translational Medicine, 47(1), pp.28~35 (2013), 대한병리학회
72. Setia N, "A protein and mRNA expression-based classification of gastric cancer", Mod Pathol, 29, pp.772~784 (2016)
73. Ahn S, "High-throughput protein and mRNA expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications", Am J Surg Pathol, 41, pp.106~115 (2017)
74. Cho J, "Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability", ESMO Open, 3, pp.e000326~ (2018)
75. Kim ST, "Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer", Nat Med, 24, pp.1449~1458 (2018)
76. Lee J, "Biomarkers for gastric cancer : molecular classification revisited", Precis Future Med, 1, pp.59~68 (2017)
77. 이혜승, "Molecular Testing for Gastrointestinal Cancer", Journal of Pathology and Translational Medicine, 51(2), pp.103~121 (2017), 대한병리학회[DOI]
78. Murphy KM, "Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers", J Mol Diagn, 8, pp.305~311 (2006)
79. Campanella NC, "Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population : correlation with ancestry markers", Eur J Hum Genet, 22, pp.875~880 (2014)
80. 배윤성, "Usefulness of Immunohistochemistry for Microsatellite Instability Screening in Gastric Cancer", Gut and Liver, 9(5), pp.629~635 (2015), 거트앤리버 소화기연관학회협의회
81. Normanno N, "Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial", Ann Oncol, 26, pp.1710~1714 (2015)
82. Vanderwalde A, "Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11, 348 patients", Cancer Med, 7, pp.746~756 (2018)
83. Lee HS, "Epstein-barr viruspositive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma", Clin Cancer Res, 10, pp.1698~1705 (2004)
84. Kang BW, "Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer", Ann Oncol, 27, pp.494~501 (2016)
85. 조준훈, "Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response", Journal of Gastric Cancer, 16(1), pp.1~7 (2016), 대한위암학회[DOI]
86. Derks S, "Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers", Oncotarget, 7, pp.32925~32932 (2016)
87. Naseem M, "Outlooks on Epstein-Barr virus associated gastric cancer", Cancer Treat Rev, 66, pp.15~22 (2018)
88. Yau TO, "Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma : disease and treatments", World J Gastroenterol, 20, pp.6448~6456 (2014)
89. Ambinder RF, "Epstein-Barr-encoded RNA in situ hybridization : diagnostic applications", Hum Pathol, 25, pp.602~605 (1994)
90. Gulley ML, "Molecular diagnosis of Epstein-Barr virus-related diseases", J Mol Diagn, 3, pp.1~10 (2001)
91. Chen XZ, "Epstein-Barr virus infection and gastric cancer : a systematic review", Medicine (Baltimore), 94, pp.e792~ (2015)
92. Melendez B, "Methods of measurement for tumor mutational burden in tumor tissue", Transl Lung Cancer Res, 7, pp.661~667 (2018)
93. Van Allen EM, "Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine", Nat Med, 20, pp.682~688 (2014)
94. Rizvi NA, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
95. Snyder A, "Genetic basis for clinical response to CTLA-4 blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
96. Hellmann MD, "Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden", N Engl J Med, 378, pp.2093~2104 (2018)
97. Steuer CE, "Tumor mutation burden: leading immunotherapy to the era of precision medicine?", J Clin Oncol, 36, pp.631~632 (2018)
98. Wang F, "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemorefractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib", II clinical trial NCT02915432, 2019, pp.30, 1479~1486
99. Griffith M, "Optimizing cancer genome sequencing and analysis", Cell Syst, 1, pp.210~223 (2015)
100. Chalmers ZR, "Analysis of 100, 000human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
101. He Y, "Lymphocyte-activation gene-3, an important immune checkpoint in cancer", Cancer Sci, 107, pp.1193~1197 (2016)
102. Woo SR, "Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape", Cancer Res, 72, pp.917~927 (2012)
103. Coutzac C, "Immunotherapy in advanced gastric cancer, is it the future?", Crit Rev Oncol Hematol, 133, pp.25~32 (2019)
104. Zhu C, "The Tim-3 ligand galectin-9negatively regulates T helper type 1 immunity", Nat Immunol, 6, pp.1245~1252 (2005)
105. Yanai H, "HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses", Nature, 462, pp.99~103 (2009)
106. Sakuishi K, "Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity", J Exp Med, 207, pp.2187~2194 (2010)
107. Prendergast GC, "Indoleamine 2, 3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer", Cancer Immunol Immunother, 63, pp.721~735 (2014)
108. Hornyak L, "The Role of Indoleamine-2, 3-Dioxygenase in Cancer Development, Diagnostics, and Therapy", Front Immunol, 9, pp.151~ (2018)
109. Terness P, "Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells : mediation of suppression by tryptophan metabolites", J Exp Med, 196, pp.447~457 (2002)
110. Spranger S, "Mechanism of tumor rejection with doublets of CTLA-4, PD-1", PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+)T cells directly within the tumor microenvironment, 2014, pp.2, 3~
111. Zaretsky JM, "Mutations associated with acquired resistance to PD-1 blockade in melanoma", N Engl J Med, 375, pp.819~829 (2016)
112. Chowell D, "Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy", Science, 359, pp.582~587 (2018)

관련 논문AI추천